Prime Medicine, Inc. Operating Cash Flow
Prime Medicine, Inc. (PRME) reported Operating Cash Flow of -$83.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Prime Medicine, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$41.05M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$42.71M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$37.26M, a 329.34% decline year-over-year.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$35.04M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$162.56M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$122.86M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$165.41M.
- Prime Medicine, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$131.83M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$83.76M 10-Q · filed 2026-08-06 | -$121.01M derived: sum of 3 quarters · filed 2026-08-06 | -$156.05M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$42.71M 10-Q · filed 2026-05-07 | -$79.97M derived: sum of 2 quarters · filed 2026-05-07 | -$115.00M derived: sum of 3 quarters · filed 2026-05-07 | -$156.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$37.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$72.30M derived: sum of 2 quarters · filed 2026-03-03 | -$113.71M derived: sum of 3 quarters · filed 2026-08-06 | -$162.56M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$35.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$76.45M derived: sum of 2 quarters · filed 2026-08-06 | -$125.31M 10-Q · filed 2025-11-07 | -$109.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$41.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$90.27M 10-Q · filed 2026-08-06 | -$74.02M derived: sum of 3 quarters · filed 2026-08-06 | -$99.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$48.86M 10-Q · filed 2026-05-07 | -$32.61M derived: sum of 2 quarters · filed 2026-05-07 | -$58.52M derived: sum of 3 quarters · filed 2026-05-07 | -$104.02M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $16.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$9.67M derived: sum of 2 quarters · filed 2026-03-03 | -$55.16M derived: sum of 3 quarters · filed 2026-03-03 | -$122.86M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$25.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$71.40M derived: sum of 2 quarters · filed 2025-11-07 | -$139.11M 10-Q · filed 2025-11-07 | -$182.97M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$45.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$113.20M 10-Q · filed 2025-08-07 | -$157.06M derived: sum of 3 quarters · filed 2025-08-07 | -$196.23M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$67.71M 10-Q · filed 2025-05-08 | -$111.57M derived: sum of 2 quarters · filed 2025-05-08 | -$150.74M derived: sum of 3 quarters · filed 2025-05-08 | -$191.56M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$43.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$83.03M derived: sum of 2 quarters · filed 2025-02-28 | -$123.85M derived: sum of 3 quarters · filed 2025-02-28 | -$165.41M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$39.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$79.99M derived: sum of 2 quarters · filed 2024-11-12 | -$121.55M 10-Q · filed 2024-11-12 | -$152.26M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$40.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$82.38M 10-Q · filed 2024-08-08 | -$113.09M derived: sum of 3 quarters · filed 2024-08-08 | -$143.19M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$41.56M 10-Q · filed 2024-05-10 | -$72.27M derived: sum of 2 quarters · filed 2024-05-10 | -$102.37M derived: sum of 3 quarters · filed 2024-05-10 | -$122.59M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$30.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$60.81M derived: sum of 2 quarters · filed 2024-03-01 | -$81.03M derived: sum of 3 quarters · filed 2024-03-01 | -$131.83M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$30.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$50.32M derived: sum of 2 quarters · filed 2023-11-03 | -$101.11M 10-Q · filed 2023-11-03 | -$114.30M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$20.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$71.02M 10-Q · filed 2023-08-07 | -$84.20M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | -$50.79M 10-Q · filed 2023-05-11 | -$63.98M derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$13.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$34.08M 10-K · filed 2023-03-09 | ||
| 2021-09-30 | -$20.89M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$5.54M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |